Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. HUBS
3. TRMD
4. SPY
5. AUTO
6. MCD
7. VRTS
8. ABEO
9. MRK
10. NVDA

Go back to Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera
(NASDAQ: PTGX) Delayed: 143.70 --0 (-0%)
Previous Close $143.70    52 Week High $24.52 
Open $143.70    52 Week Low $10.02 
Day High $143.70    P/E N/A 
Day Low $143.70    EPS $0.00 
Volume 239